Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DOXYCYCLINE vs EVOXAC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.
Empiric treatment of acute bacterial exacerbations of COPD,Community-acquired pneumonia,Prostatitis caused by Chlamydia trachomatis,Treatment of Lyme disease,Treatment of Rocky Mountain spotted fever,Acne vulgaris (off-label),Malaria prophylaxis (off-label)
Treatment of dry mouth symptoms in patients with Sjögren's syndrome,Off-label: Management of radiation-induced xerostomia
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
30 mg orally three times daily.
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
The terminal elimination half-life is approximately 1 hour. Due to its short half-life, multiple daily dosing is required for sustained pharmacological effect.
Doxycycline is partially metabolized in the liver via unspecified pathways; it is not significantly metabolized by CYP450 enzymes. Approximately 40% is excreted renally as active drug.
Primarily metabolized by CYP2D6 and CYP3A3/4; also undergoes N-oxidation and hydroxylation.
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Approximately 50% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion; the remaining 50% is metabolized by ester hydrolysis and excreted as inactive metabolites in urine.
80–93% bound to plasma proteins, primarily albumin.
Approximately 50-60% bound to plasma proteins, primarily albumin.
0.75–1.3 L/kg, indicating extensive tissue penetration; high concentrations in lung, liver, bone, and prostate.
Volume of distribution is approximately 6 L/kg, indicating extensive distribution into tissues beyond plasma water.
Oral: 90–100% (well absorbed); IV: 100%; topical: minimal systemic absorption (<10%).
Oral bioavailability is approximately 30% due to extensive first-pass metabolism.
For Cr Cl < 50 m L/min: no dosage adjustment required for most indications; for severe infections or prolonged use, consider monitoring renal function. In patients with Cr Cl < 10 m L/min, reduce dose or avoid if possible due to potential anti-anabolic effect.
For GFR <30 m L/min: not recommended due to increased systemic exposure.
Child-Pugh A: no adjustment. Child-Pugh B: use with caution; no specific dose reduction recommended. Child-Pugh C: avoid use due to lack of safety data.
No adjustment required for mild to moderate hepatic impairment; not studied in severe impairment.
For children >8 years and weighing ≤45 kg: 2.2 mg/kg every 12 hours on day 1, then 2.2 mg/kg once daily or 1.1 mg/kg every 12 hours. For children >45 kg: same as adult. For children <8 years: contraindicated due to risk of permanent tooth discoloration and enamel hypoplasia.
Safety and efficacy not established; no recommended dose.
No specific dose adjustment required; use standard adult dosing. Monitor renal function and consider potential increased risk of photosensitivity reactions. Avoid in elderly with impaired renal function if alternative agents available.
No specific dose adjustment; monitor for increased anticholinergic effects due to age-related reduced clearance.
There is no FDA black box warning for doxycycline.
None.
Photosensitivity: avoid prolonged sun exposure,Esophageal injury: take with adequate fluids,Hepatotoxicity: caution in hepatic impairment,Intracranial hypertension: risk of pseudotumor cerebri,Delay in bone growth and tooth discoloration in children <8 years,C. difficile-associated diarrhea,Superinfection with resistant organisms
Cardiovascular effects: May cause bradycardia, AV block, hypotension; use caution in patients with cardiovascular disease.,Pulmonary effects: Can exacerbate asthma, chronic bronchitis, or COPD due to increased bronchial secretions.,Ophthalmic effects: May impair night vision or cause visual disturbances; caution when driving at night.,Renal impairment: Not recommended in severe renal impairment (Cr Cl <30 m L/min).,Hepatic impairment: Caution in moderate to severe hepatic disease.,Potential for sweating and dehydration: Monitor fluid intake.,Drug interactions: Concomitant use with beta-blockers or other cholinergic agents may increase risk of bradycardia.
Hypersensitivity to tetracyclines,Children <8 years of age (except for anthrax or severe infections),Pregnancy (especially second and third trimesters)
Uncontrolled asthma,Narrow-angle glaucoma,Acute iritis,Hypersensitivity to cevimeline or any component,Concurrent use with certain anticholinergics (e.g., atropine) due to antagonistic effects
Dairy products (milk, cheese, yogurt), calcium-fortified foods, antacids containing aluminum, calcium, magnesium, and iron supplements can chelate doxycycline, reducing absorption. Separate intake by at least 2 hours. Alcohol is not known to interact significantly. Avoid taking with high-iron foods like spinach or red meat within 2 hours.
No significant food interactions; may be taken with or without food. However, high-fat meals may delay absorption but not overall effect.
Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use associated with neural tube defects, cardiovascular malformations, and spontaneous abortion. Hepatic necrosis in pregnant women reported.
Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variations at doses 2-4 times the maximum recommended human dose. First trimester: Potential risk, use only if benefit justifies risk. Second trimester: Limited data, avoid unless necessary. Third trimester: No specific fetal risks identified, but monitor for maternal cholinergic effects.
Doxycycline is excreted into breast milk in low concentrations (M/P ratio ~0.2-0.6). Theoretical risk of dental staining and bone growth suppression in nursing infants. American Academy of Pediatrics considers compatible with breastfeeding due to low absorption, but alternative antibiotics preferred.
Unknown if excreted in human breast milk. M/P ratio not available. Caution advised due to potential for cholinergic side effects in nursing infants. Consider discontinuing nursing or drug, taking into account importance of drug to mother.
Increased renal clearance and volume of distribution during pregnancy may reduce serum concentrations, but no dose adjustment recommended due to teratogenicity. Use only if absolutely necessary with caution.
No specific pharmacokinetic studies in pregnancy. Pregnancy may alter drug absorption and metabolism; however, no established dose adjustments. Start at lowest effective dose (30 mg three times daily) and titrate based on response and tolerability. Monitor for reduced efficacy or increased toxicity due to pregnancy-induced changes.
Administer with a full glass of water to reduce esophageal irritation; avoid lying down for 30 minutes after dosing. Tetracyclines bind calcium, so avoid dairy, antacids, and iron within 2 hours of dosing. Use sun protection due to photosensitivity. In children under 8, pregnant, or breastfeeding, avoid due to tooth discoloration and bone growth inhibition. Monitor for superinfection, especially Clostridioides difficile. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
EVOXAC (cevimeline) is a cholinergic agonist used primarily for xerostomia in Sjögren's syndrome; a key pearl is to avoid concurrent use with other parasympathomimetics due to additive effects. Monitor for excessive sweating, bradycardia, and bronchospasm, especially in patients with asthma or COPD. Contraindicated in uncontrolled asthma, iritis, and angle-closure glaucoma. Dose reduction may be required in renal impairment.
Take exactly as prescribed; finish the full course even if you feel better.,Take with a full glass of water and remain upright for 30 minutes after.,Avoid dairy products, antacids, calcium supplements, iron, and magnesium within 2 hours of taking doxycycline.,Use sunscreen and protective clothing; avoid prolonged sun exposure as it can cause severe sunburn.,Do not take if pregnant, breastfeeding, or if you have a child under 8 years old.,Report any signs of severe diarrhea, skin rash, or difficulty swallowing to your doctor.,Store at room temperature away from moisture and heat; do not use outdated medication.
Take exactly as prescribed, usually three times daily with or without food.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause blurred vision or dizziness.,Report excessive sweating, abdominal cramps, slow heart rate, or difficulty breathing to your healthcare provider immediately.,Do not use with other medications that increase saliva or tear production without consulting your doctor.,Store at room temperature away from moisture and heat.
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Ketobemidone, an opioid analgesic, may inhibit the cytochrome P450 enzyme CYP3A4, which is involved in the metabolism of doxycycline. This can lead to reduced clearance and increased plasma concentrations of doxycycline, potentially enhancing its antibiotic effects or increasing the risk of adverse effects such as photosensitivity, gastrointestinal disturbances, or hepatic toxicity."
"Clobazam, a benzodiazepine and CYP3A4 inducer, may increase the metabolism of doxycycline, a tetracycline antibiotic, reducing its plasma concentration and potentially compromising its antibacterial efficacy. This interaction could lead to subtherapeutic doxycycline levels, increasing the risk of treatment failure or microbial resistance. Conversely, doxycycline may inhibit CYP3A4, potentially elevating clobazam concentrations, though the clinical significance of this effect is less clear."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DOXYCYCLINE vs EVOXAC, answered by our medical review team.
DOXYCYCLINE is a Tetracycline Antibiotic that works by Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-t RNA to the m RNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.. EVOXAC is a Cholinergic Agonist that works by Cevimeline is a cholinergic agonist with affinity for muscarinic receptors, primarily M1 and M3 subtypes. Stimulation of these receptors increases exocrine gland secretion, including salivary and sweat glands.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DOXYCYCLINE and EVOXAC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DOXYCYCLINE is: 100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.. The standard adult dose of EVOXAC is: 30 mg orally three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DOXYCYCLINE and EVOXAC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DOXYCYCLINE is classified as Category D/X. Category D. Avoid in pregnancy. Risk of fetal harm including permanent tooth discoloration and impaired bone growth when used in second and third trimesters. First trimester use as. EVOXAC is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. In animal studies, cevimeline (active ingredient) produced decreased fetal body weights and increased skeletal variatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.